Gilead Sciences
Most Read
How much longer will Gilead wait before buying its way out of the doldrums?
State Medicaid programs continue to restrict access to hepatitis C drugs
Which drug makers do a good job getting poor patients access to their medicines?
Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?
Gilead asks FDA to expand exclusivity for a key HIV drug
Less than 1 percent of state prisoners with hepatitis C get treated due to drug costs
European regulator amends some Gilead hep C patent claims
All Coverage
advertisement
